Table 5.

Palliative chemotherapy received by patients with angiosarcoma.

Clinical characteristics	n
Received palliative chemotherapy
Yes	71 (47.3%)
No	76 (50.7%)
Unknown	3 (2.0%)
Lines of palliative chemotherapy
1	41 (57.7%)
2	12 (16.9%)
≥3	18 (25.4%)
First-line palliative chemotherapy
Paclitaxel	53 (74.6%)
Doxorubicin-based†	12 (16.9%)
Other‡	6 (8.5%)
Second-line palliative chemotherapy
Paclitaxel	6 (20.0%)
Doxorubicin-based††	18 (60.0%)
Other‡‡	6 (20.0%)
Response to first-line chemotherapy by radiological and/or clinical assessment§	Overall (n = 60)	Paclitaxel			Doxorubicin-based* (n = 11)
		AS-HN (n = 31)	Other (n = 14)	Any site (n = 45)
Progressive disease	14 (23.3%)	3 (9.7%)	2 (14.3%)	5 (11.1%)	7 (63.6%)
Stable disease	14 (23.3%)	5 (16.1%)	5 (35.7%)	10 (22.2%)	2 (18.2%)
Partial response	32 (53.3%)	23 (74.2%)	7 (50.0%)	30 (66.7%)	2 (18.2%)
Response to first-line chemotherapy by radiological assessment only¶	Overall (n = 47)	Paclitaxel			Doxorubicin-based (n = 8)
		AS-HN (n = 27)	Other (n = 11)	Any site (n = 38)
Progressive disease	9 (19.1%)	3 (11.1%)	2 (18.2%)	5 (13.2%)	4 (50.0%)
Stable disease	11 (23.4%)	3 (11.1%)	5 (45.5%)	8 (21.1%)	2 (25.0%)
Partial response	27 (57.4%)	21 (77.8%)	4 (36.4%)	25 (65.8%)	2 (25.0%)

^†Doxorubicin plus ifosfamide (n = 3), doxorubicin alone (n = 2) and liposomal doxorubicin (n = 7).

^‡Ifosfamide (n = 1), thalidomide (n = 2), sunitinib (n = 1) and unknown (n = 2).

^††Liposomal doxorubicin (n = 17) and doxorubicin alone (n = 1).

^‡‡Gemcitabine plus cisplatin (n = 1), thalidomide plus cyclophosphamide (n = 1), bevacizumab (n = 3) and unknown (n = 1).

^*Only 1 AS-HN primary with progressive disease.

^§All patients with response documentation, including by clinical evaluation only (n = 13).

^¶Includes only patients with response documentation as assessed by radiological imaging.

Abbreviations: AS-HN, angiosarcoma of the head and neck.